NASDAQ:EQ
Equillium Inc. Stock News
$1.56
+0.0200 (+1.30%)
At Close: May 17, 2024
Equillium to Present at the JonesTrading 2023 Healthcare Summit
08:00am, Monday, 02'nd Oct 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium to Present at the Cantor Fitzgerald Global Healthcare & LD Micro Main Event Conferences
08:00am, Wednesday, 20'th Sep 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammatory dis
Equillium to Attend Wells Fargo Healthcare Conference & Present at H.C. Wainwright 25th Annual Global Investor Conference
08:00am, Wednesday, 30'th Aug 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat
Equillium, Inc. (EQ) Reports Q2 Loss, Tops Revenue Estimates
06:59pm, Wednesday, 09'th Aug 2023
Equillium, Inc. (EQ) came out with a quarterly loss of $0.10 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to loss of $0.41 per share a year ago.
Equillium Announces $7.5 Million Share Repurchase Program
04:00pm, Wednesday, 02'nd Aug 2023
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company leveraging a deep understanding of immunobiology to develop novel therapeutics to treat
Equillium, Inc. (EQ) Reports Q1 Loss, Tops Revenue Estimates
07:02pm, Thursday, 11'th May 2023
Equillium, Inc. (EQ) came out with a quarterly loss of $0.11 per share versus the Zacks Consensus Estimate of a loss of $0.20. This compares to loss of $0.45 per share a year ago.
Equillium to Present at Two Upcoming Investor Conferences
08:00am, Tuesday, 08'th Nov 2022
LA JOLLA, Calif.
Why Is Equillium (EQ) Stock Soaring 20% Today?
02:20pm, Tuesday, 27'th Sep 2022
Clinical-stage biotechnology firm Equillium (NASDAQ: EQ ), which focuses on developing novel therapeutics to treat severe autoimmune and inflammatory disorders, released encouraging clinical data rega
Equillium's stock is up 12% after sharing early data about its investigational lupus treatment
08:15am, Tuesday, 27'th Sep 2022
Shares of Equillium Inc. EQ, -3.98% gained 12.9% in premarket trading on Tuesday after the company shared a batch of interim data from an early stage trial evaluating its experimental treatment in 13
Equillium to Present at Two Upcoming Investor Conferences
08:00am, Wednesday, 31'st Aug 2022
LA JOLLA, Calif.--(BUSINESS WIRE)---- $EQ #GVHD--Equillium, Inc. (Nasdaq: EQ), a clinical-stage biotechnology company focused on developing novel therapeutics to treat severe autoimmune and inflammato
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)
02:00pm, Tuesday, 29'th Mar 2022 Zacks Investment Research
Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi
Down 20.5% in 4 Weeks, Here's Why You Should You Buy the Dip in Equillium, Inc. (EQ)
11:17am, Tuesday, 29'th Mar 2022
Equillium, Inc. (EQ) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revi
Equillium begins phase 3 trial of itolizumab for graft versus host disease
02:12pm, Friday, 04'th Mar 2022 Seeking Alpha
Equillium Inc (EQ) said it had begun a Phase 3 trial of its drug, itolizumab, in patients with acute graft-versus-host disease (aGVHD). aGVHD is an inflammatory response by the…
Equillium Adds Three Drugs To Its Pipeline Via Bioniz Acquisition
04:22pm, Wednesday, 16'th Feb 2022 Benzinga
Equillium Inc (NASDAQ: EQ ), with only one asset in its pipeline , is expanding its drug development efforts via the acquisition of Bioniz Therapeutics . The deal, worth approximately $330 million, gives the biotech access to three therapeutics. Equillium will buy Bioniz in an all-stock deal for around 5.69 million shares and up to $57.5 million in development biobucks. The deal … Full story available on Benzinga.com
Equillium acquires Bioniz Therapeutics in all-stock deal
12:19pm, Wednesday, 16'th Feb 2022 Seeking Alpha
Equillium (EQ) acquired Bioniz Therapeutics, granting EQ exclusive worldwide rights to all current and future Bioniz products.The consideration is comprised of an all-stock upfront…
